CN118236279A - Fusobacterium composition - Google Patents
Fusobacterium composition Download PDFInfo
- Publication number
- CN118236279A CN118236279A CN202311766674.8A CN202311766674A CN118236279A CN 118236279 A CN118236279 A CN 118236279A CN 202311766674 A CN202311766674 A CN 202311766674A CN 118236279 A CN118236279 A CN 118236279A
- Authority
- CN
- China
- Prior art keywords
- fusobacterium
- composition
- mass
- present disclosure
- lauryl sulfate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 91
- 241000605909 Fusobacterium Species 0.000 title claims abstract description 52
- 150000003839 salts Chemical class 0.000 claims abstract description 30
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 claims abstract description 20
- 229940043264 dodecyl sulfate Drugs 0.000 claims abstract description 20
- 230000001954 sterilising effect Effects 0.000 claims abstract description 17
- AVBJHQDHVYGQLS-AWEZNQCLSA-N (2s)-2-(dodecanoylamino)pentanedioic acid Chemical compound CCCCCCCCCCCC(=O)N[C@H](C(O)=O)CCC(O)=O AVBJHQDHVYGQLS-AWEZNQCLSA-N 0.000 claims abstract description 15
- 230000000844 anti-bacterial effect Effects 0.000 claims description 52
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 28
- IJALWSVNUBBQRA-UHFFFAOYSA-N 4-Isopropyl-3-methylphenol Chemical compound CC(C)C1=CC=C(O)C=C1C IJALWSVNUBBQRA-UHFFFAOYSA-N 0.000 claims description 18
- NFIDBGJMFKNGGQ-UHFFFAOYSA-N isopropylmethylphenol Natural products CC(C)CC1=CC=CC=C1O NFIDBGJMFKNGGQ-UHFFFAOYSA-N 0.000 claims description 18
- 235000001968 nicotinic acid Nutrition 0.000 claims description 16
- 229960003512 nicotinic acid Drugs 0.000 claims description 16
- 239000011664 nicotinic acid Substances 0.000 claims description 16
- 206010006326 Breath odour Diseases 0.000 claims description 10
- 208000032139 Halitosis Diseases 0.000 claims description 9
- 239000004359 castor oil Substances 0.000 claims description 5
- 235000019438 castor oil Nutrition 0.000 claims description 5
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 5
- 229940071145 lauroyl sarcosinate Drugs 0.000 claims description 5
- 239000002324 mouth wash Substances 0.000 claims description 4
- 229940051866 mouthwash Drugs 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 6
- -1 alkali metal salt Chemical class 0.000 description 36
- 239000003899 bactericide agent Substances 0.000 description 28
- 241000894006 Bacteria Species 0.000 description 27
- 239000007788 liquid Substances 0.000 description 22
- 230000000052 comparative effect Effects 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 12
- 210000003296 saliva Anatomy 0.000 description 12
- 208000006558 Dental Calculus Diseases 0.000 description 10
- 235000014113 dietary fatty acids Nutrition 0.000 description 10
- 229930195729 fatty acid Natural products 0.000 description 10
- 239000000194 fatty acid Substances 0.000 description 10
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 10
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 9
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 238000002156 mixing Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 239000002202 Polyethylene glycol Substances 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 229910052708 sodium Inorganic materials 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 159000000000 sodium salts Chemical class 0.000 description 5
- 241000193403 Clostridium Species 0.000 description 4
- 241000605986 Fusobacterium nucleatum Species 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 229910052783 alkali metal Inorganic materials 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 208000028169 periodontal disease Diseases 0.000 description 4
- GKQHIYSTBXDYNQ-UHFFFAOYSA-M 1-dodecylpyridin-1-ium;chloride Chemical compound [Cl-].CCCCCCCCCCCC[N+]1=CC=CC=C1 GKQHIYSTBXDYNQ-UHFFFAOYSA-M 0.000 description 3
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 3
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 3
- 108010014251 Muramidase Proteins 0.000 description 3
- 102000016943 Muramidase Human genes 0.000 description 3
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 3
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229960003237 betaine Drugs 0.000 description 3
- JMGZBMRVDHKMKB-UHFFFAOYSA-L disodium;2-sulfobutanedioate Chemical compound [Na+].[Na+].OS(=O)(=O)C(C([O-])=O)CC([O-])=O JMGZBMRVDHKMKB-UHFFFAOYSA-L 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000004325 lysozyme Substances 0.000 description 3
- 235000010335 lysozyme Nutrition 0.000 description 3
- 229960000274 lysozyme Drugs 0.000 description 3
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- 239000006072 paste Substances 0.000 description 3
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- SVIJYLPSHPPVQF-UHFFFAOYSA-N 2-[2,2-diaminoethyl(dodecyl)amino]acetic acid Chemical compound CCCCCCCCCCCCN(CC(N)N)CC(O)=O SVIJYLPSHPPVQF-UHFFFAOYSA-N 0.000 description 2
- AXCXHFKZHDEKTP-NSCUHMNNSA-N 4-methoxycinnamaldehyde Chemical compound COC1=CC=C(\C=C\C=O)C=C1 AXCXHFKZHDEKTP-NSCUHMNNSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 241001291923 Fusobacterium nucleatum subsp. nucleatum Species 0.000 description 2
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 2
- ZYEMGPIYFIJGTP-UHFFFAOYSA-N O-methyleugenol Chemical compound COC1=CC=C(CC=C)C=C1OC ZYEMGPIYFIJGTP-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 241000605862 Porphyromonas gingivalis Species 0.000 description 2
- YUJLIIRMIAGMCQ-CIUDSAMLSA-N Ser-Leu-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YUJLIIRMIAGMCQ-CIUDSAMLSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical class OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 239000003945 anionic surfactant Substances 0.000 description 2
- IRERQBUNZFJFGC-UHFFFAOYSA-L azure blue Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[S-]S[S-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-] IRERQBUNZFJFGC-UHFFFAOYSA-L 0.000 description 2
- FUWUEFKEXZQKKA-UHFFFAOYSA-N beta-thujaplicin Chemical compound CC(C)C=1C=CC=C(O)C(=O)C=1 FUWUEFKEXZQKKA-UHFFFAOYSA-N 0.000 description 2
- 239000006161 blood agar Substances 0.000 description 2
- XSIFPSYPOVKYCO-UHFFFAOYSA-N butyl benzoate Chemical compound CCCCOC(=O)C1=CC=CC=C1 XSIFPSYPOVKYCO-UHFFFAOYSA-N 0.000 description 2
- NEHNMFOYXAPHSD-UHFFFAOYSA-N citronellal Chemical compound O=CCC(C)CCC=C(C)C NEHNMFOYXAPHSD-UHFFFAOYSA-N 0.000 description 2
- JOZKFWLRHCDGJA-UHFFFAOYSA-N citronellol acetate Chemical compound CC(=O)OCCC(C)CCC=C(C)C JOZKFWLRHCDGJA-UHFFFAOYSA-N 0.000 description 2
- MWKFXSUHUHTGQN-UHFFFAOYSA-N decan-1-ol Chemical compound CCCCCCCCCCO MWKFXSUHUHTGQN-UHFFFAOYSA-N 0.000 description 2
- 239000000551 dentifrice Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- MTZQAGJQAFMTAQ-UHFFFAOYSA-N ethyl benzoate Chemical compound CCOC(=O)C1=CC=CC=C1 MTZQAGJQAFMTAQ-UHFFFAOYSA-N 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 2
- 239000001685 glycyrrhizic acid Substances 0.000 description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 2
- 235000019410 glycyrrhizin Nutrition 0.000 description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 235000019477 peppermint oil Nutrition 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 2
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 2
- 229940083466 soybean lecithin Drugs 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- 239000000606 toothpaste Substances 0.000 description 2
- RUVINXPYWBROJD-ONEGZZNKSA-N trans-anethole Chemical compound COC1=CC=C(\C=C\C)C=C1 RUVINXPYWBROJD-ONEGZZNKSA-N 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 1
- QYIXCDOBOSTCEI-QCYZZNICSA-N (5alpha)-cholestan-3beta-ol Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 QYIXCDOBOSTCEI-QCYZZNICSA-N 0.000 description 1
- KRLBLPBPZSSIGH-CSKARUKUSA-N (6e)-3,7-dimethylnona-1,6-dien-3-ol Chemical compound CC\C(C)=C\CCC(C)(O)C=C KRLBLPBPZSSIGH-CSKARUKUSA-N 0.000 description 1
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 1
- WUOACPNHFRMFPN-SECBINFHSA-N (S)-(-)-alpha-terpineol Chemical compound CC1=CC[C@@H](C(C)(C)O)CC1 WUOACPNHFRMFPN-SECBINFHSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WEEGYLXZBRQIMU-UHFFFAOYSA-N 1,8-cineole Natural products C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- UFNOUKDBUJZYDE-UHFFFAOYSA-N 2-(4-chlorophenyl)-3-cyclopropyl-1-(1H-1,2,4-triazol-1-yl)butan-2-ol Chemical compound C1=NC=NN1CC(O)(C=1C=CC(Cl)=CC=1)C(C)C1CC1 UFNOUKDBUJZYDE-UHFFFAOYSA-N 0.000 description 1
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- XGRSAFKZAGGXJV-UHFFFAOYSA-N 3-azaniumyl-3-cyclohexylpropanoate Chemical compound OC(=O)CC(N)C1CCCCC1 XGRSAFKZAGGXJV-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- WJLVQTJZDCGNJN-UHFFFAOYSA-N Chlorhexidine hydrochloride Chemical compound Cl.Cl.C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 WJLVQTJZDCGNJN-UHFFFAOYSA-N 0.000 description 1
- 244000037364 Cinnamomum aromaticum Species 0.000 description 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 1
- JOZKFWLRHCDGJA-LLVKDONJSA-N Citronellyl acetate Natural products CC(=O)OCC[C@H](C)CCC=C(C)C JOZKFWLRHCDGJA-LLVKDONJSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 239000005757 Cyproconazole Substances 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- IELOKBJPULMYRW-NJQVLOCASA-N D-alpha-Tocopheryl Acid Succinate Chemical compound OC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C IELOKBJPULMYRW-NJQVLOCASA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 235000001809 DL-alpha-tocopherylacetate Nutrition 0.000 description 1
- 239000011626 DL-alpha-tocopherylacetate Substances 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 208000002064 Dental Plaque Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 101000925662 Enterobacteria phage PRD1 Endolysin Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- WEEGYLXZBRQIMU-WAAGHKOSSA-N Eucalyptol Chemical compound C1C[C@H]2CC[C@]1(C)OC2(C)C WEEGYLXZBRQIMU-WAAGHKOSSA-N 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- 239000001329 FEMA 3811 Substances 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000019501 Lemon oil Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 235000004347 Perilla Nutrition 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical class OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- MSCCTZZBYHQMQJ-AZAGJHQNSA-N Tocopheryl nicotinate Chemical compound C([C@@](OC1=C(C)C=2C)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC1=C(C)C=2OC(=O)C1=CC=CN=C1 MSCCTZZBYHQMQJ-AZAGJHQNSA-N 0.000 description 1
- 206010044029 Tooth deposit Diseases 0.000 description 1
- 241000589892 Treponema denticola Species 0.000 description 1
- 241000589884 Treponema pallidum Species 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- 102100029469 WD repeat and HMG-box DNA-binding protein 1 Human genes 0.000 description 1
- 101710097421 WD repeat and HMG-box DNA-binding protein 1 Proteins 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- WAUOTJNSQGJSSL-UQKRIMTDSA-N [(2s)-2-(methylamino)propanoyl] dodecanoate;sodium Chemical compound [Na].CCCCCCCCCCCC(=O)OC(=O)[C@H](C)NC WAUOTJNSQGJSSL-UQKRIMTDSA-N 0.000 description 1
- JVOGSHDZLOJKKR-MXFMKSRJSA-I [Na+].[Na+].[Na+].[Mg++].CCc1c(C)c2cc3[n-]c(c(C)c3C=C)c(C)c3nc(C[C@H]3CCC([O-])=O)c(CC([O-])=O)c3[n-]c(cc1n2)c(C)c3C([O-])=O Chemical compound [Na+].[Na+].[Na+].[Mg++].CCc1c(C)c2cc3[n-]c(c(C)c3C=C)c(C)c3nc(C[C@H]3CCC([O-])=O)c(CC([O-])=O)c3[n-]c(cc1n2)c(C)c3C([O-])=O JVOGSHDZLOJKKR-MXFMKSRJSA-I 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- OVKDFILSBMEKLT-UHFFFAOYSA-N alpha-Terpineol Natural products CC(=C)C1(O)CCC(C)=CC1 OVKDFILSBMEKLT-UHFFFAOYSA-N 0.000 description 1
- TUFYVOCKVJOUIR-UHFFFAOYSA-N alpha-Thujaplicin Natural products CC(C)C=1C=CC=CC(=O)C=1O TUFYVOCKVJOUIR-UHFFFAOYSA-N 0.000 description 1
- QYIXCDOBOSTCEI-UHFFFAOYSA-N alpha-cholestanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 QYIXCDOBOSTCEI-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229940088601 alpha-terpineol Drugs 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 229940011037 anethole Drugs 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 229910052586 apatite Inorganic materials 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- UDEWPOVQBGFNGE-UHFFFAOYSA-N benzoic acid n-propyl ester Natural products CCCOC(=O)C1=CC=CC=C1 UDEWPOVQBGFNGE-UHFFFAOYSA-N 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229960004504 chlorhexidine hydrochloride Drugs 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 229960005233 cineole Drugs 0.000 description 1
- 229940117916 cinnamic aldehyde Drugs 0.000 description 1
- KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 description 1
- 239000010630 cinnamon oil Substances 0.000 description 1
- 229930003633 citronellal Natural products 0.000 description 1
- 235000000983 citronellal Nutrition 0.000 description 1
- 239000001926 citrus aurantium l. subsp. bergamia wright et arn. oil Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000010634 clove oil Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 229940108928 copper Drugs 0.000 description 1
- 229940099418 d- alpha-tocopherol succinate Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-N diphosphoric acid Chemical compound OP(O)(=O)OP(O)(O)=O XPPKVPWEQAFLFU-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- 239000010643 fennel seed oil Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229940091249 fluoride supplement Drugs 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000003731 gingival crevicular fluid Anatomy 0.000 description 1
- 229960001269 glycine hydrochloride Drugs 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- DCYOBGZUOMKFPA-UHFFFAOYSA-N iron(2+);iron(3+);octadecacyanide Chemical compound [Fe+2].[Fe+2].[Fe+2].[Fe+3].[Fe+3].[Fe+3].[Fe+3].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] DCYOBGZUOMKFPA-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000010501 lemon oil Substances 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 229930007744 linalool Natural products 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000001683 mentha spicata herb oil Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- OLXYLDUSSBULGU-UHFFFAOYSA-N methyl pyridine-4-carboxylate Chemical compound COC(=O)C1=CC=NC=C1 OLXYLDUSSBULGU-UHFFFAOYSA-N 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 229940116837 methyleugenol Drugs 0.000 description 1
- PRHTXAOWJQTLBO-UHFFFAOYSA-N methyleugenol Natural products COC1=CC=C(C(C)=C)C=C1OC PRHTXAOWJQTLBO-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 229940114937 microcrystalline wax Drugs 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 229940074371 monofluorophosphate Drugs 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- ITVGXXMINPYUHD-CUVHLRMHSA-N neohesperidin dihydrochalcone Chemical compound C1=C(O)C(OC)=CC=C1CCC(=O)C(C(=C1)O)=C(O)C=C1O[C@H]1[C@H](O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 ITVGXXMINPYUHD-CUVHLRMHSA-N 0.000 description 1
- 229940089953 neohesperidin dihydrochalcone Drugs 0.000 description 1
- 235000010434 neohesperidine DC Nutrition 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000007823 ocimene derivatives Chemical class 0.000 description 1
- KSCKTBJJRVPGKM-UHFFFAOYSA-N octan-1-olate;titanium(4+) Chemical compound [Ti+4].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-] KSCKTBJJRVPGKM-UHFFFAOYSA-N 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- AXCXHFKZHDEKTP-UHFFFAOYSA-N para-methoxycinnamaldehyde Natural products COC1=CC=C(C=CC=O)C=C1 AXCXHFKZHDEKTP-UHFFFAOYSA-N 0.000 description 1
- RUVINXPYWBROJD-UHFFFAOYSA-N para-methoxyphenyl Natural products COC1=CC=C(C=CC)C=C1 RUVINXPYWBROJD-UHFFFAOYSA-N 0.000 description 1
- 229940056211 paraffin Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 description 1
- 230000003239 periodontal effect Effects 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- ONQDVAFWWYYXHM-UHFFFAOYSA-M potassium lauryl sulfate Chemical compound [K+].CCCCCCCCCCCCOS([O-])(=O)=O ONQDVAFWWYYXHM-UHFFFAOYSA-M 0.000 description 1
- 229940116985 potassium lauryl sulfate Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229960003351 prussian blue Drugs 0.000 description 1
- 239000013225 prussian blue Substances 0.000 description 1
- 229940005657 pyrophosphoric acid Drugs 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 239000010668 rosemary oil Substances 0.000 description 1
- 229940058206 rosemary oil Drugs 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 239000010670 sage oil Substances 0.000 description 1
- 108700004121 sarkosyl Proteins 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000011775 sodium fluoride Substances 0.000 description 1
- 235000013024 sodium fluoride Nutrition 0.000 description 1
- 229960000414 sodium fluoride Drugs 0.000 description 1
- 229940045944 sodium lauroyl glutamate Drugs 0.000 description 1
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 1
- 229940045885 sodium lauroyl sarcosinate Drugs 0.000 description 1
- 229960004711 sodium monofluorophosphate Drugs 0.000 description 1
- 239000004317 sodium nitrate Substances 0.000 description 1
- 235000010344 sodium nitrate Nutrition 0.000 description 1
- IWIUXJGIDSGWDN-UQKRIMTDSA-M sodium;(2s)-2-(dodecanoylamino)pentanedioate;hydron Chemical compound [Na+].CCCCCCCCCCCC(=O)N[C@H](C([O-])=O)CCC(O)=O IWIUXJGIDSGWDN-UQKRIMTDSA-M 0.000 description 1
- SLBXZQMMERXQAL-UHFFFAOYSA-M sodium;1-dodecoxy-4-hydroxy-1,4-dioxobutane-2-sulfonate Chemical compound [Na+].CCCCCCCCCCCCOC(=O)C(S(O)(=O)=O)CC([O-])=O SLBXZQMMERXQAL-UHFFFAOYSA-M 0.000 description 1
- ZUFONQSOSYEWCN-UHFFFAOYSA-M sodium;2-(methylamino)acetate Chemical compound [Na+].CNCC([O-])=O ZUFONQSOSYEWCN-UHFFFAOYSA-M 0.000 description 1
- KSVSZLXDULFGDQ-UHFFFAOYSA-M sodium;4-aminobenzenesulfonate Chemical compound [Na+].NC1=CC=C(S([O-])(=O)=O)C=C1 KSVSZLXDULFGDQ-UHFFFAOYSA-M 0.000 description 1
- PVGBHEUCHKGFQP-UHFFFAOYSA-N sodium;n-[5-amino-2-(4-aminophenyl)sulfonylphenyl]sulfonylacetamide Chemical compound [Na+].CC(=O)NS(=O)(=O)C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 PVGBHEUCHKGFQP-UHFFFAOYSA-N 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000019721 spearmint oil Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- ANOBYBYXJXCGBS-UHFFFAOYSA-L stannous fluoride Chemical compound F[Sn]F ANOBYBYXJXCGBS-UHFFFAOYSA-L 0.000 description 1
- 229960002799 stannous fluoride Drugs 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229940104261 taurate Drugs 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 229950009883 tocopheryl nicotinate Drugs 0.000 description 1
- XJPBRODHZKDRCB-UHFFFAOYSA-N trans-alpha-ocimene Natural products CC(=C)CCC=C(C)C=C XJPBRODHZKDRCB-UHFFFAOYSA-N 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 239000009637 wintergreen oil Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- JLQFVGYYVXALAG-CFEVTAHFSA-N yasmin 28 Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.C([C@]12[C@H]3C[C@H]3[C@H]3[C@H]4[C@@H]([C@]5(CCC(=O)C=C5[C@@H]5C[C@@H]54)C)CC[C@@]31C)CC(=O)O2 JLQFVGYYVXALAG-CFEVTAHFSA-N 0.000 description 1
- 239000002888 zwitterionic surfactant Substances 0.000 description 1
- 229930007845 β-thujaplicin Natural products 0.000 description 1
Landscapes
- Cosmetics (AREA)
Abstract
Fusobacterium composition. [ problem ] to provide a method capable of effectively sterilizing Fusobacterium. [ solution ] A composition for sterilizing Fusobacterium, comprising: (A) Lauryl sulfate, and (B) at least one selected from the group consisting of lauroyl glutamic acid and salts thereof.
Description
Technical Field
The present disclosure relates to a composition for sterilizing fusobacterium bacteria, and the like.
Background
Dental plaque (plaque) is a biofilm formed by the accumulation of microorganisms in the oral cavity, and is considered to be a cause of dental caries and periodontal disease. Thus, tartar control, and in particular inhibition of tartar formation, is important.
Generally, tartar is formed as follows. That is, a thin film of protein derived from saliva and physiological gingival crevicular fluid called "pellicle (Pellicle)" is first formed on the surface of the tooth, and facultative anaerobic bacteria (initial attachment bacteria) such as streptococcus are attached to the tooth surface through the pellicle. The initial attachment bacteria attach to mediator bacteria such as fusobacterium which are co-aggregated with various oral bacteria, and the later attachment bacteria such as Porphyromonas gingivalis (Porphyromonas gingivalis) and Treponema pallidum (Treponema denticola) which are anaerobic bacteria attach to/aggregate with the mediator bacteria, so that the tartar is mature. In particular, late-stage adhesion bacteria cause periodontal disease, and are known to be directly or indirectly involved in periodontal tissue destruction (for example, non-patent document 1).
Further, it has been reported that fusobacterium bacteria produce hydrogen sulfide, which is a main cause of bad breath (for example, non-patent document 2).
Prior art literature
Patent literature
Patent document 1: japanese patent laid-open No. 2022-097295
Non-patent literature
Non-patent document 1: j Dent Res 90 (11): 1271-1278,2011
Non-patent literature 2:mBio Volume 13,Issue 5(September/October 2022Volume 13Issue 5e01936-22)"Genetic Determinants of Hydrogen Sulfide Biosynthesis in Fusobacterium nucleatum Are Required for Bacterial Fitness,Antibiotic Sensitivity,and Virulence"
Disclosure of Invention
Problems to be solved by the invention
From the above, it can be said that effective sterilization of fusobacterium is important in preventing and/or improving periodontal disease and halitosis. Accordingly, the present inventors have studied a method capable of effectively sterilizing fusobacterium.
Solution for solving the problem
The present inventors have found that lauryl sulfate exerts an excellent bactericidal effect against fusobacterium bacteria, and have further studied for improving the bactericidal effect. As a result, it was found that the antibacterial effect of fusobacterium was further improved by combining lauroyl glutamic acid or a salt thereof with lauryl sulfate. Further studies have been conducted to find that the bactericidal effect of fusobacterium is further improved when isopropyl methylphenol and/or nicotinic acid or a salt thereof is further combined with lauryl sulfate and lauroyl glutamic acid or a salt thereof.
The present disclosure includes, for example, the subject matter described in the following items.
Item 1.
A composition for sterilizing fusobacterium bacteria, comprising:
(A) Lauryl sulfate
(B) At least one selected from the group consisting of lauroyl glutamic acid and salts thereof.
Item 2.
The composition of item 1, further comprising isopropyl methylphenol.
Item 3.
The composition of item 1 or 2, further comprising niacin or a salt thereof.
Item 4.
The composition according to item 3, which contains 10 parts by mass or less of nicotinic acid or a salt thereof per 1 part by mass of the component (B).
Item 5.
The composition according to any one of items 1 to 4, further comprising lauroyl sarcosinate and/or polyoxyethylated hydrogenated castor oil.
Item 6.
The composition according to any one of items 1 to 5, which is an oral composition.
Item 7.
The composition according to any one of claims 1 to 5, which is used for preventing or improving halitosis.
Item 8.
The composition of item 6 or 7 which is a mouthwash.
ADVANTAGEOUS EFFECTS OF INVENTION
Provided is a composition capable of effectively sterilizing Fusobacterium. The composition is effective for preventing and/or improving periodontal disease and halitosis, for example.
Drawings
FIG. 1 shows the viable count of Fusobacterium when aqueous solutions of sodium lauryl sulfate of various concentrations were used as bactericides.
FIG. 2 shows the viable count of Fusobacterium when various bactericides having different compositions (Table 1) were used.
FIG. 3A shows the viable count of Fusobacterium when isopropyl methylphenol solutions of various concentrations were used as bactericides.
FIG. 3B shows the viable count of Fusobacterium when various bactericides having different compositions (Table 3) were used.
FIG. 4 shows the viable count of Fusobacterium when various bactericides having different compositions (Table 4) were used.
Detailed Description
Each embodiment included in the present disclosure is described in more detail below. The present disclosure preferably includes a composition containing (a) lauryl sulfate and (B) at least one selected from the group consisting of lauroyl glutamic acid and salts thereof, uses thereof, and the like, but is not limited thereto, and the present disclosure includes all that is disclosed in the present specification, as will be understood by those skilled in the art. A composition containing (a) lauryl sulfate and (B) at least one selected from the group consisting of lauroyl glutamic acid and salts thereof is sometimes referred to as a composition of the present disclosure. The compositions of the present disclosure are particularly useful as fusobacterium bacteria killing agents. The lauryl sulfate may be referred to as component (a) and at least one selected from the group consisting of lauroyl glutamic acid and salts thereof may be referred to as component (B).
The bacterium of the genus Fusobacterium is not particularly limited as long as it is a mediator bacterium of the initial attachment bacterium and the later attachment bacterium in the formation of tartar, and Clostridium nucleatum (Fusobacterium nucleatum) is preferably exemplified.
The lauryl sulfate is preferably an alkali metal salt, an ammonium salt, or a triethanolamine salt of lauryl sulfate, more preferably sodium lauryl sulfate or potassium lauryl sulfate, and still more preferably sodium lauryl sulfate. The lauryl sulfate may be used alone or in combination of 2 or more.
The composition of the present disclosure preferably contains lauryl sulfate, for example, 0.01 to 0.5 mass%. The upper limit or the lower limit of the range may be, for example, 0.02, 0.05, 0.1, 0.2, 0.3, or 0.4 mass%. For example, the content may be 0.02 to 0.4 mass%.
The salt of lauroyl glutamic acid is preferably an alkali metal salt, an ammonium salt, or a triethanolamine salt, more preferably a sodium salt or a potassium salt, and further preferably a sodium salt. As lauroyl glutamic acid and salts thereof, 1 or 2 or more types may be used singly or in combination.
The composition of the present disclosure preferably contains the component (B) for example, 0.01 to 5 mass%. The upper or lower limit of the range may be, for example, 0.02, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, or 4.5 mass%. For example, the content may be 0.02 to 4% by mass.
The composition of the present disclosure preferably contains the component (B) and the component (A) in a mass ratio (B: A) of 1:0.1 to 5. The upper or lower limit of the range (0.1 to 5) may be, for example, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.5, 2, 2.5, 3, 3.5, 4, or 4.5. The range may be, for example, 0.2 to 4 or 0.3 to 2.
The compositions of the present disclosure preferably also contain isopropyl methylphenol (IPMP). Isopropyl methylphenol is preferable because it can further improve the bactericidal effect of Fusobacterium obtained by combining the component (A) and the component (B).
When the composition of the present disclosure contains isopropyl methylphenol, it is preferable to contain 0.001 to 2 parts by mass per 1 part by mass of the component (B). The upper or lower limit of the range (0.001 to 2) may be 0.002、0.003、0.004、0.005、0.006、0.007、0.008、0.009、0.01、0.02、0.03、0.04、0.05、0.06、0.07、0.08、0.09、0.1、0.2、0.3、0.4、0.5、0.6、0.7、0.8、0.9、1、1.1、1.2、1.3、1.4、1.5、1.6、1.7、1.8 or 1.9, for example. For example, the range may be 0.002 to 1.5 or 0.005 to 1.
In the case where the composition of the present disclosure contains isopropyl methylphenol, it is preferable to contain 0.005 to 0.2% by mass. The upper or lower limit of the range may be 0.006、0.007、0.008、0.009、0.01、0.02、0.03、0.04、0.05、0.06、0.07、0.08、0.09、0.1、0.11、0.12、0.13、0.14、0.15、0.16、0.17、0.18、 or 0.19 mass%, for example. For example, the content may be 0.01 to 0.15 mass%.
The compositions of the present disclosure preferably further comprise niacin or a salt thereof. Nicotinic acid or a salt thereof is preferable because it can further improve the bactericidal effect of Fusobacterium obtained by combining the component (A) and the component (B).
The nicotinic acid salt is preferably an alkali metal salt, more preferably a sodium salt or a potassium salt, and further preferably a sodium salt. As the nicotinic acid or a salt thereof, 1 or 2 or more kinds may be used singly or in combination. Among them, niacin is preferred.
When the composition of the present disclosure contains nicotinic acid or a salt thereof, it is preferably contained in an amount of 10 parts by mass or less, more preferably 0.002 to 10 parts by mass, relative to 1 part by mass of the component (B). The upper limit or the lower limit of the range (0.002 to 10) may be 0.005、0.01、0.05、0.1、0.2、0.3、0.4、0.5、0.6、0.7、0.8、0.9、1、1.5、2、2.5、3、3.5、4、4.5、5、5.5、6、6.5、7、7.5、8、8.5、9、 or 9.5, for example. For example, the range may be 0.2 to 8 or 0.3 to 5.
In the case where the composition of the present disclosure contains nicotinic acid or a salt thereof, it preferably contains 0.01 to 2% by mass. The upper or lower limit of the range may be 0.02、0.03、0.04、0.05、0.06、0.07、0,08、0.09、0.1、0.2、0.3、0.4、0.5、0.6、0.7、0.8、0.9、1、1.1、1.2、1.3、1.4、1.5、1.6、1.7、1.8、 or 1.9 mass%, for example. For example, the content may be 0.1 to 1.5 mass%.
The composition of the present disclosure contains a component (a) useful for sterilizing fusobacterium and a component (B) capable of improving the bactericidal activity of fusobacterium lauryl sulfate, and thus can be preferably used for sterilizing fusobacterium. Furthermore, isopropyl methylphenol and/or nicotinic acid or a salt thereof can further enhance the fusobacterium sterilization by the combination of the component (a) and the component (B), and a composition further comprising these can be more preferably used as a fusobacterium sterilization composition.
In addition, as described above, it can be said that formation of tartar on the tooth surface can be suppressed by sterilizing fusobacterium bacteria, and therefore the composition of the present disclosure can be preferably used as a composition for inhibiting formation of tartar. Further, as described above, since it is reported that clostridium produces hydrogen sulfide, which is a main causative substance of halitosis, and1 species of clostridium is causative bacteria of halitosis, it can be said that halitosis can be prevented or ameliorated by sterilizing clostridium, and therefore the composition of the present disclosure can be preferably used as a composition for preventing and/or ameliorating halitosis. Thus, from this, it is clear that the composition of the present disclosure can be preferably used as an oral composition. The composition for oral cavity can be used preferably for inhibiting dental calculus formation, sterilizing Fusobacterium, and preventing and/or improving halitosis.
The compositions of the present disclosure can be solid compositions, liquid compositions. The composition can be used as a drug or quasi drug, for example. In addition, the form of the composition of the present disclosure is not particularly limited, and forms (dosage forms) such as ointments, pastes, dermatological pastes, gels, liquid preparations, sprays, mouthwash liquid preparations, liquid dentifrices, toothpastes, chewing gums, and the like may be formed according to conventional methods. Among them, mouthwash liquid preparations, liquid dentifrices, toothpastes, ointments, pastes, liquid preparations, gels are preferred.
The composition of the present disclosure may further contain, for example, any of the components alone or 2 or more components capable of being compounded into an oral composition, within a range that does not impair the effect.
For example, as the surfactant, a nonionic surfactant, an anionic surfactant, or an amphoteric surfactant may be compounded. Specifically, examples of the nonionic surfactant include sugar fatty acid esters such as sucrose fatty acid esters, maltose fatty acid esters, and lactose fatty acid esters; fatty acid alkanolamides; a glycerol fatty acid ester; sorbitan fatty acid esters; fatty acid monoglycerides; polyoxyethylene alkyl ether with polyoxyethylene addition coefficient of 8-10 and alkyl carbon number of 13-15; polyoxyethylene alkylphenyl ether having a polyoxyethylene addition coefficient of 10 to 18 and an alkyl group having 9 carbon atoms; diethyl sebacate; polyoxyethylene hydrogenated castor oil; fatty acid polyoxyethylene sorbitan, and the like. Examples of the anionic surfactant include sulfate salts such as sodium polyoxyethylene lauryl ether sulfate; sodium lauryl sulfosuccinate, sodium polyoxyethylene lauryl ether sulfosuccinate and other sulfosuccinates; acyl amino acid salts such as sodium cocoyl sarcosinate and sodium lauroyl methylalaninate; sodium cocoyl methyl taurate, and the like. Examples of the zwitterionic surfactant include acetic acid betaine type surfactants such as lauryl dimethyl amino acid betaine and coco fatty acid amidopropyl dimethyl amino acid betaine; imidazoline-type active agents such as N-cocoyl-N-carboxymethyl-N-hydroxyethyl ethylenediamine sodium; amino acid type active agents such as N-lauryldiaminoethylglycine, etc. These surfactants may be compounded alone or in combination of 2 or more. The amount to be compounded is usually 0.1 to 5% by mass based on the total amount of the composition. Although not particularly limited, the composition of the present disclosure preferably contains polyoxyethylene hydrogenated castor oil. The polyoxyethylene addition coefficient is preferably about 20 to 80, more preferably about 30 to 60. The polyoxyethylene hydrogenated castor oil preferably contains, for example, 0.05 to 2% by mass.
Examples of the flavoring agents include menthol, carboxylic acid, anethole, eugenol, methyl salicylate, limonene, ocimene, n-decanol, citronellal, α -terpineol, methyl acetate, citronellyl acetate, methyl eugenol, eucalyptol, linalool, ethyl linalool, thymol, spearmint oil, peppermint oil, lemon oil, orange oil, sage oil, rosemary oil, cassia oil, perilla oil, wintergreen oil, clove oil, eucalyptus oil, multi-bergamot oil, d-camphor, fennel oil, cinnamon oil, cinnamaldehyde, peppermint oil, and vanillin. These may be compounded singly or in combination of 2 or more kinds, for example, in an amount of 0.001 to 1.5% by mass relative to the total amount of the composition.
As the sweetener, sodium saccharin, potassium acesulfame, stevioside, neohesperidin dihydrochalcone, perillyl, thaumatin, aspartyl phenylalanine methyl ester, p-methoxycinnamaldehyde, and the like can be used, for example. They may be compounded, for example, in an amount of 0.01 to 1% by mass relative to the total amount of the composition.
Further, as the wetting agent, 2 or more kinds of sorbitol, ethylene glycol, propylene glycol, glycerin, 1, 3-butanediol, polypropylene glycol, xylitol, maltitol, lactitol, polyoxyethylene glycol, and the like may be blended singly or in combination.
As the preservative, there may be blended methyl benzoate, ethyl benzoate, propyl benzoate, butyl benzoate and other parabens, sodium benzoate, phenoxyethanol, alkyldiaminoethyl glycine hydrochloride and the like.
The colorant may be mixed with a legal pigment such as blue No. 1, yellow No. 4, red No. 202, green No. 3, a mineral pigment such as ultramarine, enhanced ultramarine, prussian blue, or the like, titanium oxide, or the like.
As the pH adjuster, phosphoric acid, malic acid, pyrophosphoric acid, lactic acid, tartaric acid, glycerophosphoric acid, acetic acid, nitric acid, or chemically acceptable salts thereof, sodium hydroxide, or the like may be blended. They may be compounded alone or in combination of 2 or more in such a manner that the pH of the composition is in the range of 4 to 8, preferably 5 to 7. The blending amount of the pH adjustor may be, for example, 0.01 to 2 wt%.
In the composition of the present disclosure, not only dodecylpyridinium chloride but also 2 or more enzymes such as dl- α -tocopherol acetate, tocopherol succinate, tocopherol nicotinate and the like, an amphoteric bactericide such as dodecyldiaminoethyl glycine and the like, a nonionic bactericide such as triclosan and hinokitiol, an anionic bactericide such as lauroyl sarcosinate, a cationic bactericide such as cetylpyridinium chloride, chlorhexidine hydrochloride, benzalkonium chloride, benzethonium chloride, glucanase, amylase, protease, non-water-soluble glucanase, lysozyme (lysozyme), enzymes such as lysozyme (lytic enzyme), alkali metal monofluorophosphate such as sodium monofluorophosphate, sodium fluoride, fluoride such as stannous fluoride, fluorochromic acid, epsilon-aminocaproic acid, chlorohydroxy allantoin aluminum, dihydrocholesterol, glycyrrhetinic acid, glycyrrhizic acid, copper chlorophyllin sodium, glycerophosphate, chlorophyll, sodium chloride, carropeptide, sodium nitrate, sodium sulfonate, sodium sulfanilate, cyproconazole, and the like may be blended as the active ingredient.
Although not particularly limited, lauroyl sarcosinate (preferably sodium or potassium salt, more preferably sodium salt) is preferably contained in the composition of the present disclosure. The lauroyl sarcosinate is preferably contained in an amount of 0.01 to 2% by mass, for example.
Further, alcohols, silicon, apatite, white vaseline, paraffin, liquid paraffin, microcrystalline wax, squalane, liquid paraffin, and a polyethylene compound ointment base (plasitibase) may be added as the base.
In addition, the compositions of the present disclosure may be prepared using known methods or methods readily contemplated by known methods. For example, it can be prepared by appropriately mixing dodecylpyridinium chloride with glycyrrhizic acid or a salt thereof, and other components as required.
The object to which the composition of the present disclosure is applied is not particularly limited, and human and non-human mammals are preferably exemplified. The non-human mammal is preferably livestock, pet, or the like, and more specifically, dogs, cats, mice, rats, horses, cows, sheep, monkeys, or the like, for example, may be mentioned. In addition, the composition of the present disclosure is not particularly limited, and as described above, since the dodecylpyridinium chloride can effectively sterilize fusobacterium which is a mediator bacterium, it can be said that the composition is particularly suitable for application to an oral cavity of a subject in which tartar is not formed or in the middle of formation (in which post-attachment bacteria are not attached).
The composition of the present disclosure can be applied directly to, for example, a composition for inhibiting tartar formation which is not used as an oral composition, or a composition containing the fusobacterium bactericide (for example, when the composition is used for cleaning a denture).
The term "comprising" in this specification also includes "consisting essentially of … …" and "consisting of … …" (The term "comprised" included "consisting essentially of" and "consisting of."). In addition, the present disclosure includes any combination of the constituent conditions described in the present specification.
In addition, when the subject matter contained in the present disclosure is specified with respect to various characteristics (properties, structures, functions, and the like) described in the above embodiments of the present disclosure, any combination may be adopted. That is, the present disclosure includes all subjects including any combination of the characteristics that can be combined as described in the present specification.
Examples (example)
The following examples are shown to more specifically describe embodiments of the present disclosure, but embodiments of the present disclosure are not limited by the following examples. In the following diagrams, sodium lauryl sulfate may be referred to as SLS, sodium lauroyl sarcosinate as LS, sodium lauroyl glutamate as LG, and nicotinic acid as NA. The values of the components in the table represent mass% unless otherwise specified.
An aqueous solution of 0.05 mass%, 0.1 mass%, 0.5 mass%, or 1.0 mass% of sodium lauryl sulfate was produced to form a bactericide liquid.
The bactericide liquids of the comparative examples and examples were produced according to the compositions shown in table 1. In the compositions of each of examples and comparative examples shown in table 1, sodium saccharin, polyethylene glycol (PEG), and polyoxyethylene alkyl (12 to 14) sodium sulfosuccinate 2 were added in appropriate amounts in addition to the components shown in table 1, and water was added thereto to form 100 mass% of the total. These components were added in equal amounts to each other in any case.
TABLE 1
In addition, 2 subspecies of the following Fusobacterium were used as test bacteria.
Bacteria 1: fusobacterium nucleatum subspecies (Fusobacterium nucleatum subsp. Nucleatum) ATCC23726
Bacteria 2: fusobacterium nucleatum subspecies (Fusobacterium nucleatum subsp. Nucleatum) ATCC25586
Study 1
The test bacteria were inoculated into 10ml of GAM broth (Nikkin pharmaceutical Co., ltd.) and cultured anaerobically at 37℃for 2 days. The culture solution was used as a test bacterial solution.
200. Mu.l of a test bacterial solution was mixed with 200. Mu.l of aqueous sodium lauryl sulfate solutions (disinfectant solutions) having different concentrations. After 30 seconds from the mixing, 100. Mu.l of the mixture was collected, 900. Mu.l of PBS for inactivation of the drug was added (10-fold dilution of the mixture), and the bactericidal effect of the bactericide was inactivated. The drug-inactivated PBS was prepared by adding soybean lecithin and Tween 80 to phosphate-buffered saline (PBS) so that the final concentrations thereof were 0.07% and 0.5%. The mixture was diluted in stages with the agent-inactivated PBS, and the mixture was diluted 10 1~107 times (stage mixture dilution).
The produced dilutions of the step mixture were spread on sheep blood agar medium (Becton, dickinson and Company, japan) for CDC anaerobe, and anaerobically cultured at 37℃for 3 days, and the number of viable bacteria was counted. From the obtained results, log (viable count) CFU/ml was calculated. Note that Log is a common logarithm.
The results are shown in FIG. 1. The results when water was used instead of the aqueous sodium lauryl sulfate solution are also shown. It is known that lauryl sulfate exerts the bactericidal effect of fusobacterium.
Study 2
For the test bacteria, each of Fusobacterium (bacteria 1 or 2) was inoculated into 10ml of GAM broth (Nikki pharmaceutical Co., ltd.) and cultured anaerobically at 37℃for 2 days. After cultivation, a bacterial density of about 10 8~109 CFU/ml was obtained. The culture broth was centrifuged (3000 rpm,10 min, 4 ℃) and the supernatant was discarded and the cells (about 10 9~1010 CFU) recovered.
10Ml of resting saliva was collected from 1 healthy adult, and the cell was mixed with the saliva (about 10 9~1010 CFU). After mixing, the mixture was uniformly dispersed to produce Fn with high saliva content (about 10 8~109 CFU/saliva 1 ml). Fn represents "Fusobacterium".
The respective bactericide liquids (bactericides of respective examples shown in table 1) having different concentrations were mixed with Fn to contain saliva. The mixing ratio was set to be Fn high with saliva=1:1 (200. Mu.L: 200. Mu.L) or 1:9 (100. Mu.L: 900. Mu.L) as the bactericide liquid. After 30 seconds from the mixing, 100. Mu.l of the mixture was collected, 900. Mu.l of PBS for inactivation of the drug was added (10-fold dilution of the mixture), and the bactericidal effect of the bactericide was inactivated. The drug-inactivated PBS was prepared by adding soybean lecithin and Tween 80 to phosphate-buffered saline (PBS) so that the final concentrations thereof were 0.07% and 0.5%.
Each 100. Mu.l of the prepared mixture was smeared on sheep blood agar medium (Becton, dickinson and Company, japan) for CDC anaerobic bacteria, and anaerobic culture was performed at 37℃for 3 days, and the number of viable bacteria was counted. From the obtained results, log (viable count) CFU/ml was calculated. Note that Log is a common logarithm.
The results are shown in Table 2 and FIG. 2. The results were obtained by conducting a study using a mixture ratio of bacteria 2, a bactericide liquid and Fn, which is high in saliva, of 1:9. The results of using a 0.2 mass% aqueous solution of sodium lauryl sulfate as the bactericide liquid and using water instead of the bactericide liquid are also shown.
TABLE 2
Log (viable count) CFU/ml | |
0.2% SLS aqueous solution | 6.35 |
Comparative example 1a | 6.37 |
Comparative example 2a | 6.31 |
Comparative example 3a | 6.47 |
Comparative example 4a | 6.28 |
Comparative example 5a | 6.50 |
Comparative example 6a | 7.60 |
Example 1a | 4.32 |
Example 2a | 4.44 |
Comparative example 7a | 6.50 |
Comparative example 8a | 6.60 |
Water and its preparation method | 7.02 |
Since only the bactericidal activity of the fusobacterium of examples 1a and 2a was improved, it was found that the bactericidal effect of the fusobacterium by lauryl sulfate was enhanced by the combined use of lauroyl glutamic acid or a salt thereof.
In addition, 0.025 mass% or 0.05 mass% solution of isopropyl methylphenol (IPMP) was produced, and the bactericidal activity against fusobacterium was studied using the method of study 1 described above, using this as a bactericidal agent. The isopropyl methylphenol solution was an aqueous ethanol solution having a final concentration of 10 mass%.
Further, the bactericidal liquid of each comparative example and example was produced according to the composition shown in table 3, and the bactericidal activity against fusobacterium was studied using Fn high-content saliva as described above. In the compositions of examples and comparative examples shown in table 3, sodium saccharin, polyethylene glycol (PEG), and polyoxyethylene alkyl (12 to 14) sodium sulfosuccinate 2 were added in appropriate amounts in addition to the components shown in table 3, and water was added thereto to form 100 mass% of the total. These components were added in equal amounts to each other in any case.
TABLE 3
The results when using an isopropyl methylphenol solution as a bactericide are shown in fig. 3A. The results were obtained by conducting a study using a mixing ratio of 1:1 of the bacteria 1, the bactericide liquid and the test bacteria liquid. In addition, the results obtained when a 10 mass% aqueous ethanol solution was used in place of the isopropyl methylphenol solution are also shown.
The results of using the bactericides of each example described in table 3 are shown in fig. 3B. The results were obtained by conducting a study using a mixture ratio of bacteria 1, a bactericide liquid and Fn, which is high in saliva, of 1:9. The results when water was used instead of the bactericide liquid are also shown.
From these results, it is understood that isopropyl methylphenol does not exert the bactericidal effect of fusobacterium, but the bactericidal effect of fusobacterium is further enhanced by further combining isopropyl methylphenol with lauryl sulfate and lauroyl glutamic acid or a salt thereof.
Further, the bactericidal liquid of each comparative example and example was produced according to the composition shown in table 4, and the bactericidal activity against fusobacterium was studied using Fn high-content saliva as described above. In the compositions of examples and comparative examples shown in table 4, sodium saccharin, polyethylene glycol (PEG), and polyoxyethylene alkyl (12 to 14) sodium sulfosuccinate 2 were added in appropriate amounts in addition to the components shown in table 4, and water was added thereto to form 100 mass% of the total. These components were added in equal amounts to each other in any case.
TABLE 4
The results are shown in FIG. 4. The results were obtained by conducting a study using a mixture ratio of bacteria 1, a bactericide liquid and Fn, which is high in saliva, of 1:9. The results when water was used instead of the bactericide liquid are also shown.
From the results, it is understood that the bactericidal effect of fusobacterium can be further enhanced by further combining niacin with lauryl sulfate and lauroyl glutamic acid or a salt thereof. It is also unexpectedly found that the effect of enhancing the bactericidal effect is highly likely to be low in the amount of nicotinic acid.
Claims (8)
1. (A) Lauryl sulfate
(B) At least one selected from the group consisting of lauroyl glutamic acid and salts thereof
The application in the manufacture of the composition for sterilizing Fusobacterium.
2. (A) Lauryl sulfate,
(B) At least one selected from the group consisting of lauroyl glutamic acid and salts thereof, and
Isopropyl methylphenol and/or nicotinic acid or salts thereof
The application in the manufacture of the composition for sterilizing Fusobacterium.
3. (A) Lauryl sulfate,
(B) At least one selected from the group consisting of lauroyl glutamic acid and salts thereof, and
Isopropyl methylphenol and niacin or salts thereof
The application in the manufacture of the composition for sterilizing Fusobacterium.
4. The use according to claim 2 or 3, wherein 10 parts by mass or less of nicotinic acid or a salt thereof is used with respect to 1 part by mass of the component (B).
5. Use according to claim 1,2 or 3, wherein the fusobacterium bactericidal composition further comprises lauroyl sarcosinate and/or polyoxyethylated hydrogenated castor oil.
6. The use according to claim 1, 2 or 3, wherein the fusobacterium bactericidal composition is an oral composition.
7. The use according to claim 1, 2 or 3, wherein the fusobacterium bactericidal composition is for halitosis prevention or improvement.
8. The use according to claim 1, 2 or 3, wherein the fusobacterium bactericidal composition is a mouthwash.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022207577A JP2024091118A (en) | 2022-12-23 | 2022-12-23 | Composition for killing Fusobacterium |
JP2022-207577 | 2022-12-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN118236279A true CN118236279A (en) | 2024-06-25 |
Family
ID=91551698
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311766674.8A Pending CN118236279A (en) | 2022-12-23 | 2023-12-21 | Fusobacterium composition |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP2024091118A (en) |
CN (1) | CN118236279A (en) |
-
2022
- 2022-12-23 JP JP2022207577A patent/JP2024091118A/en active Pending
-
2023
- 2023-12-21 CN CN202311766674.8A patent/CN118236279A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2024091118A (en) | 2024-07-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5815502B2 (en) | Antibacterial composition comprising 4-isopropyl-3-methylphenol and zinc ions | |
Williams | The antibacterial and antiplaque effectiveness of mouthwashes containing cetylpyridinium chloride with and without alcohol in improving gingival health | |
AU2010363657B2 (en) | Oral care product and methods of use and manufacture thereof | |
JP5730025B2 (en) | Oral composition | |
JP2000256155A (en) | Oral composition | |
US6110445A (en) | Oral composition exhibiting improved uptake and retention of antibacterial compounds on dental tissue surfaces | |
JP7134770B2 (en) | oral composition | |
JP2022058280A (en) | Composition for inhibiting plaque formation | |
CN118236279A (en) | Fusobacterium composition | |
DE69314454T2 (en) | Antibacterial oral care product against plaque formation | |
JP2004238375A (en) | Bactericidal composition used for oral cavity | |
WO2022071457A1 (en) | Composition for inhibiting plaque formation | |
JP6968964B1 (en) | Composition for suppressing plaque formation | |
JP2003012483A (en) | Composition for oral cavity application | |
JPH06239723A (en) | Composition for oral cavity | |
JP3821037B2 (en) | Periodontal pathogen adhesion inhibitor and composition for oral cavity having periodontal pathogen adhesion inhibitory action | |
JP7159265B2 (en) | Anti-periodontal disease composition | |
JP2022158544A (en) | Bactericidal composition | |
JP7143198B2 (en) | oral composition | |
KR20020082308A (en) | Composition for the mouth containing extraction of Euonymus alatus Sieb | |
JP2023177682A (en) | Plaque formation inhibitory composition | |
JP2000229823A (en) | Composition for oral cavity | |
JP2022158545A (en) | Bactericidal composition | |
JP3660169B2 (en) | Oral composition | |
JP3877412B2 (en) | Liquid oral composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination |